Taking Psychedelics Seriously
Journal of Palliative Medicine January 22, 2018 DOI: 10.1089/jpm.2017.0684 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | Anxiety Psilocybin |
| Keywords | Terminally ill Palliative care Depression economics Compassionate use Psychotherapist Hallucinogen Nursing Clinical trial |
| Citations | 164 |
| Key points | Argues that political, regulatory, and industry challenges impede the legitimate use of psychedelics, and that it is time to revisit their therapeutic use given precedents for access to unapproved medications and acceptance of physician-hastened death. |
Abstract
Even with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate use of psychedelics. The federal expanded access program and right-to-try laws in multiple states provide precendents for giving terminally ill patients access to medications that have not yet earned FDA approval. Given the prevalence of persistent suffering and growing acceptance of physician-hastened death as a medical response, it is time to revisit the legitimate therapeutic use of psychedelics.
Comparable studies
Other theoretical and historical papers on psilocybin for anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelics as Medicines: An Emerging New Paradigm General population | 2016 | Theoretical or philosophical paper | |
| Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy | 2022 | Theoretical or philosophical paper | |
| The Heffter Research Institute: Past and Hopeful Future | 2014 | Historical analysis | |
| Out of the box: A psychedelic model to study the creative mind | 2018 | Theoretical or philosophical paper | |
| Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa | 2021 | Theoretical or philosophical paper |
Citations in the library
Cited by 69
- The Therapeutic Potential of Psilocybin Molecules May 15, 2021
- Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing Scientific Reports January 21, 2021
- Chronic pain and psychedelics: a review and proposed mechanism of action Regional Anesthesia & Pain Medicine May 4, 2020
- Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP Addiction August 17, 2022
- Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2020
and 64 more in the library
Cites 10
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports October 13, 2017
- Potential Therapeutic Effects of Psilocybin. Neurotherapeutics July 1, 2017
- Psychedelics and connectedness Psychopharmacology August 9, 2017
and 5 more in the library